3SBio (NASDAQ: SSRX) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare 3SBio to related businesses based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, earnings and profitability.
Risk and Volatility
3SBio has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, 3SBio’s rivals have a beta of 1.03, suggesting that their average stock price is 3% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for 3SBio and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 11.76%. Given 3SBio’s rivals higher probable upside, analysts plainly believe 3SBio has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares 3SBio and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|3SBio Competitors||$564.12 million||$96.17 million||44.02|
3SBio’s rivals have higher revenue and earnings than 3SBio. 3SBio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
43.5% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares 3SBio and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
3SBio beats its rivals on 6 of the 11 factors compared.
3SBio Inc. is a biotechnology company in the People’s Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.
Receive News & Ratings for 3SBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 3SBio and related companies with MarketBeat.com's FREE daily email newsletter.